If you are a fan of growth shares, then read on!
That's because listed below are three ASX 200 growth shares that Bell Potter thinks could be among the best to buy in 2026.
Here's what it is saying about them:
Bega Cheese Ltd (ASX: BGA)
The team at Bell Potter thinks the Vegemite owner is well-placed for a period of strong growth thanks to its restructuring and strategy. Commenting on the ASX 200 growth share, it said:
Following recent restructuring announcements, with regard to the closure of Strathmerton and winding down of the PCA operations, there appears a clear pathway towards a $250-270m EBITDA target. If successful in generating this return and having consideration for the cash costs to achieve this target (c$85- 100m), it would imply a share price of $8.00-9.00ps (at BGA's historical ~12x EBITDA multiple).
In effect, BGA now has a clearly articulated strategy to generating >20% p.a. EPS growth to FY28e. Trading on a FY25-28e PEG ratio of ~1x, BGA is one of the more compelling growth exposures in the sector.
Bell Potter has a buy rating and $7.00 price target on this diversified food company's shares. Based on its current share price of $6.16, this implies potential upside of 14% for investors over the next 12 months.
Life360 Inc (ASX: 360)
Another ASX 200 growth share that Bell Potter is tipping as a buy is location technology company Life360.
While its performance in the last quarter was softer than expected, the broker believes that this will be a one off and expects it to return to form in the fourth quarter. It said:
Life360 has had a large pullback in its share price like many other stocks in the technology sector (peak of ~$55 in early October down to ~$35 in mid November). Outside of the general correction in the sector there was one factor specific to the company which also drove down the share price – slowing monthly active user or MAU growth in 3Q2025. Q3 is traditionally the strongest quarter for MAU growth so the relatively slow growth was a big surprise and was also not well explained by the company.
Outside of this number, however, everything was as expected or better and importantly paying subscriber growth was still strong. Our view is the outlook remains very positive for the company and the one quarter of relatively soft MAU growth was an aberration. We therefore expect a return to reasonable or even strong MAU growth in 4Q2025, and this could also serve as a potential catalyst for the share price.
Bell Potter has a buy rating and $52.50 price target on its shares. This suggests that upside of 57% is possible for investors between now and this time next year.
Pro Medicus Ltd (ASX: PME)
A final ASX 200 growth share that could be a buy according to Bell Potter is health imaging technology company Pro Medicus.
It thinks Pro Medicus is one of the highest quality companies on the Australian share market. And after years of strong growth, don't expect a slowdown any time soon. Bell Potter expects the explosive growth to continue. It said:
Pro Medicus is among the highest quality companies on the ASX. CY25 was yet another banner year with 10 major contract announcements, totalling minimum revenues of $445m. We expect EPS growth of 36% in FY26 followed by 30% in FY27. The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving.
Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files. The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Phillips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.
Bell Potter has a buy rating and $320.00 price target on its shares. Based on its current share price of $232.93, this implies potential upside of 37% for investors over the next 12 months.
